Assembly Biosciences, a biotechnology company based in South San Francisco, develops treatments for chronic hepatitis B and other infectious diseases, with a pipeline including multiple antiviral agents. The company, which went public in December 2010, employs 65 people.
ASMB has been in the news recently: Assembly Biosciences is not directly mentioned in the provided information. However, the article discusses New York's budget issues, including a potential $18.2 billion deficit by 2029 due to spending and tax increases, and Governor Hochul's stalled budget talks over proposed changes to discovery laws.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
